Its promise to lift flagging libidos raised hopes among women around the world. But flibanserin, the first 'female Viagra', may turn out to be a bit of a flop.
Health regulators deciding whether to give the 'pink Viagra' the green light have given it a lukewarm reception. Drug reviewers at the U.S.'s Food and Drug Administration, said that it had failed to make the grade in two studies designed to gauge its effectiveness.
Rather than making a 'significant' impact on libido, flibanserin only made sexual encounters 'slightly' more satisfying.
Source
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment